More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

The Food and Drug Administration (FDA) has approved Fasenra ® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...

AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...

That changed on Tuesday however, as the FDA signed off on Fasenra for patients with eosinophilic granulomatosis with ...

AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...

CALY-002 is under development for the treatment of eosinophilic esophagitis, celiac disease and unspecified dermatological disorders. It is a fully-humanized monoclonal antibody also administered ...

Since EGE is a heterogeneous disorder, we next assessed the relationship ... EGE (Table 1), while involvement of multiple organs by eosinophilic infiltration was seen in 52.2% (12/23) of those ...

Inflammatory disorders August 28, 2024 Editors' notes ...

Subsequent to our recent CMAJ article on oral immunotherapy,1 we received a question regarding the long-term monitoring of children who undergo this therapy for food allergies and their potential risk ...